about
Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLCGlioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2The guanine exchange factor SWAP70 mediates vGPCR-induced endothelial plasticity.Endothelial secreted factors suppress mitogen deprivation-induced autophagy and apoptosis in glioblastoma stem-like cells.Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumorsPAKing up to the endothelium.Synthetic lethality interaction between Aurora kinases and CHEK1 inhibitors in ovarian cancer.Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs.Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor.c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy.Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway.Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer.Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma.Functional transcriptomic annotation and protein-protein interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.Differential proteomic analysis of human glioblastoma and neural stem cells reveals HDGF as a novel angiogenic secreted factor.Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor geneMapping Bromodomains in breast cancer and association with clinical outcomeGenetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumorsPharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancerIdentification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancerExpression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcomeCost Effective Use of a Thiosulfinate-Enriched Allium sativum Extract in Combination with Chemotherapy in Colon CancerTrastuzumab-Targeted Biodegradable Nanoparticles for Enhanced Delivery of Dasatinib in HER2+ Metastasic Breast CancerActivity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
P50
Q28478252-C6406BEF-4B8E-4857-B048-E3E917D8EE1DQ31101680-0A572CCE-F085-4F88-8E74-6366B62668EDQ35108526-DE0CC3F4-4681-4130-9D47-4E3CDB3D7BE7Q35135190-D0276B98-9AEE-442D-B39B-FCB1594D2A49Q36363060-70DD0577-4AAE-4C61-87C2-F74AADF64518Q37589813-00884BD0-B8A7-493B-AA1D-7EC285E97D64Q38605140-749FDDCF-2A6C-4E92-88C4-4A74A7239404Q38752180-7F314C8F-A57A-4563-B343-CBCDB04BC289Q38773872-F3021B06-2857-4C78-9880-4F14E49015A6Q39659259-A3801F4E-EBCA-4DA3-907C-FE5C35B0F431Q40076507-785FEBF7-1D2C-49F6-A854-09DFCDEF8FEFQ40492947-FB966380-B1FF-4963-A32E-4C8870B72474Q42728935-D16380D8-09DD-485E-AD8F-B5050F272F9FQ48250667-7A5C321F-0A95-4A86-B50D-028237FC3015Q52149372-DC9F0A5C-B9D8-4D72-8093-352C41FAA314Q52724347-1FAECEB7-D808-4388-BC59-6BDB3E0B7B90Q55462273-0241B385-CC29-4081-A02A-4317F4E649A4Q60049618-A8C285B0-25CA-4876-91A4-DE7786D035CBQ64074543-40F3A7C9-EE6A-42F9-9BDC-8D5F53994C78Q64110339-8E4BC0B8-490F-4C98-8DE4-8F9D739FAC5DQ89595219-3C65E019-6CCC-4A7B-8FBA-46A3541965D8Q90288485-4D35998E-579E-4DA4-8138-24F2811C3D76Q90913380-E526EA95-CC77-4236-9763-EBF55FD46CFFQ92121505-6A80D3CD-2A0E-427F-BFD3-7926FD9A2C94Q92328434-AD7C2DBE-185A-4145-B9E3-CDD61DC9AEBFQ93018654-DC682145-F732-4FB2-8EB0-9D46FCBA9F56
P50
description
researcher ORCID ID = 0000-0001-5758-7592
@en
wetenschapper
@nl
name
Eva Maria Galan-Moya
@ast
Eva Maria Galan-Moya
@en
Eva Maria Galan-Moya
@es
Eva Maria Galan-Moya
@nl
type
label
Eva Maria Galan-Moya
@ast
Eva Maria Galan-Moya
@en
Eva Maria Galan-Moya
@es
Eva Maria Galan-Moya
@nl
prefLabel
Eva Maria Galan-Moya
@ast
Eva Maria Galan-Moya
@en
Eva Maria Galan-Moya
@es
Eva Maria Galan-Moya
@nl
P106
P1153
23034393600
P21
P31
P496
0000-0001-5758-7592